Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24353025 | 0.69 | PSEN1 (0.40) | CETPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28601887 | 0.69 | CETP (0.38) | CETPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6527647 | 0.69 | APP (0.45) | CETPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24352244 | 0.69 | USP2 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31362938 | 0.67 | — | — | |
| SCHEMBL24352861 | 0.67 | KMT2A (0.49) | — | |
| SCHEMBL10204660 | 0.67 | ALDH1A1 (0.44) | CETPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24352245 | 0.67 | KMT2A (0.49) | — | |
| SCHEMBL21910786 | 0.67 | CETP (0.41) | CETPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22092382 | 0.66 | TRPA1 (0.34) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | PARP1, PARP2, PARP8 | CETP 3381/4885PSEN1 3220/4885PSEN2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.